Wockhardt growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+12.0%+7.6%+5.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+65.9%+907.7%−61.4%
+141.5%+195.7%−22.7%
+449.1%+87.9%+24.0%
+534.4%+90.6%+17.4%
+5.9%+6.4%−0.4%
+13.4%+27.2%0.0%
+1,872.7%−110.0%+43.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

WOCKPHARMA₹1,922.90

Wockhardt Ltd.

· Pharma & Health
₹ CrorePeersBIOCONSYNGENEASTERDMGLANDPPLPHARMACOHANCELALPATHLABNATCOPHARMMcap ₹31,151 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+5.5+7.6+12.0—
EBITDA Growth—-61.4+907.7+65.9—
EBIT Growth—-22.7+195.7+141.5—
Net Income Growth—+24.0+87.9+449.1—
EPS Growth—+17.4+90.6+534.4—
Total Assets Growth—-0.4+6.4+5.9—
Total Equity Growth—0.0+27.2+13.4—
Cash from Operations Growth—+43.1-110.0+1,872.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.